Jam

Iovance Biotherapeutics announced five-year follow-up data for Amtagvi (lifileucel) in advanced melanoma. Results from the Phase 2 trial show deep, durable responses with one-third of patients maintaining ongoing responses after five years. Median overall survival was 13.9 months, with a five-year survival rate of 19.7%. The therapy, already FDA-approved, provides a new treatment option for patients with advanced melanoma who progressed after prior therapies.

Campbell’s Q3 net sales rose 4% to $2.5 billion, with organic growth of 1%. Adjusted EBIT increased 2% to $362 million, while adjusted EPS decreased 3% to $0.73. The company maintained its fiscal year 2025 guidance, anticipating adjusted EPS at the lower end of the range. They also returned $403 million to shareholders.

Life360 plans to issue $250 million in convertible senior notes due 2030 in a private offering to institutional buyers, with an option for an additional $37.5 million. The notes, with semi-annual interest payments, can be converted under certain conditions by holders, and Life360 can redeem them or repurchase them upon a “fundamental change.” Proceeds will finance capped call transactions (to mitigate share dilution) and general corporate purposes, potentially including acquisitions or product expansion. The specific terms and conditions will be available upon pricing.

Defense Therapeutics Inc. announced the opening of its first U.S. lab in the Boston-Cambridge area. This strategic move expands its R&D efforts within a leading biotech hub, focusing on the Accum® platform for antibody-drug conjugates (ADCs) used in cancer treatment. The Watertown facility provides access to crucial scientific resources and collaboration opportunities. Defense Therapeutics aims to establish a long-term presence in the area, aiming to strengthen its commitment to advancing their platform.

Flex LNG Ltd. announced the successful completion of a $175 million JOLCO lease financing for the Flex Courageous, generating $42 million in net proceeds and extending debt maturity to 2035, while reducing debt costs. This is the first step in the company’s refinancing program targeting three vessels with a 37-year backlog. Flex LNG plans to refinance two more vessels in 2025 to further strengthen its financial position, which is already robust with a cash balance of $410 million.

Faraday Future’s Stockholders’ Day highlighted its commitment to transparency and shareholder value. The FX Super One will launch with exclusive events in June and July, followed by a B2C rollout. The company has secured over 2,500 B2B pre-order deposits for the FX Super One, and unveiled the FX 4 design concept. FF is also expanding operations, including a new Middle East facility, and enhancing its tech and operational capabilities.

Hyundai Card has earned the UL Verified Healthy Building Mark for four of its facilities in Seoul, becoming the first cultural and leisure buildings in Asia to receive this certification. This achievement highlights their dedication to employee and guest well-being through healthier and more sustainable indoor environments, evaluated for air and water quality, as well as overall indoor environment.

Trevi Therapeutics will release topline results from its Phase 2b CORAL trial of Haduvio, an investigational therapy for chronic cough in idiopathic pulmonary fibrosis (IPF). A conference call and webcast will be held on June 2nd, 2025, at 8:30 a.m. ET to discuss the findings. Haduvio targets the cough reflex arc, and initial trials show promising reduction in cough frequency. The results are highly anticipated as there is currently no approved therapy for IPF chronic cough. Further information can be found on the company’s website.

Bicara Therapeutics presented positive Phase 1/1b trial data for ficerafusp alfa, a bifunctional antibody, combined with pembrolizumab in first-line recurrent/metastatic head and neck cancer. The results, particularly in HPV-negative patients, showed significant antitumor activity, including a median duration of response of 21.7 months, median overall survival of 21.3 months, and a two-year overall survival rate of 46%. The data supports the advancement of the FORTIFI-HN01 pivotal trial.

Arcus Biosciences’ shares surged after promising Phase 1/1b data for its casdatifan-cabozantinib combo in clear cell renal cell carcinoma (ccRCC. The ARC-20 study showed a 46% confirmed overall response rate, exceeding historic benchmarks. Arcus plans Phase 3 trials (PEAK-1) and others evaluating the combination in various ccRCC treatment settings. The positive results highlight the potential to change standards of care for patients whose ccRCC has advanced despite prior immunotherapy treatment.